Cargando…
Regeneration difficulties in patients with FQAD can limit the use of iPSc-based cell therapy
Etiopathogenesis of fluoroquinolone-associated disability (FQAD) syndrome is not fully understood, yet research could progress by utilizing induced pluripotent stem cells (iPSc) from people with this syndrome. Similarly, iPSc, or rather their derivatives, could be used in their therapy, not only for...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123688/ https://www.ncbi.nlm.nih.gov/pubmed/35598007 http://dx.doi.org/10.1186/s13287-022-02886-0 |